Fast-tracking of Tysabri questioned

THE fast-tracking of Tysabri to help the one-million sufferers of multiple sclerosis in the US needs to be questioned, said a leading stockbroker last night.

Fast-tracking of Tysabri questioned

Bloxham Stockbrokers analyst Peter Jackson noted also that Merck’s painkiller Vioxx had to be withdrawn suddenly from the market last year. Those two events coming so close together “ask a lot of questions of the FDA and its recent drug approval methods,” said Mr Jackson.

Vioxx had not been fast-tracked, but it had to have FDA approval before going to market, he said.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited